PMPaul McGreavy

Paul McGreavy

*This is an algorithmically generated author record based on publicly available information.

Paul McGreavy has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • A John Camm

    Genetic and Cardiovascular Sciences Institute, Cardiology Clinical Academic Group, St. Geroge’s University of London, Cranmer Terrace , London, SW17 0RE , UK

    1 shared publication
  • Alessandro Sionis

    Cardiology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV) , 28029 Madrid

    1 shared publication
  • Ana Gomes

    Universidade Católica Portuguesa, Center for Interrdisciplinary Research in Health , Porto

    1 shared publication
  • Andreas Zeiher

    Cardio Pulmonary Institute, Goethe University of Frankfurt , Frankfurt , Germany

    1 shared publication
  • C Aguiar

    Department of Cardiology, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Av. Prof. Dr. Reinaldo dos Santos, 2790-134 Carnaxide, Lisbon , Portugal

    1 shared publication
  • Carolyn Su Ping Lam

    National Heart Centre Singapore and Duke-National University of Singapore, Singapore

    1 shared publication

Latest Publications

  • Optimal lifelong roadmap post-ACS. A Clinical Consensus Statement of the European Association of Preventive Cardiology of the ESC

    by Roberto F E Pedretti, Emeline Van Craenenbroeck, Christiaan Vrints, Marco Ambrosetti, Donata Kurpas, Vassilios S Vassiliou, Maria Back, Trine Moholdt, Alessandro Sionis, Matthias Wilhelm, et al.

    Acute coronary syndromes (ACS) remain a major cause of mortality and morbidity across Europe, with long-term outcomes still suboptimal despite advances in acute care. Current clinical guidelines primarily focus on the immediate post-event phase, providing limited direction on extended follow-up and integrated care strategies. Furthermore, there is considerable heterogeneity across European healthcare systems regarding the implementation of post-ACS services, resulting in disparities in patient outcomes and access to preventive care. The aim of this clinical consensus statement, developed by the European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology (ESC), is to define an optimal, lifelong roadmap for patients following an ACS. It proposes a structured, phased model of care that supports evidence-informed, equitable, and patient-centred management strategies adaptable to national and local contexts. The roadmap targets multiple patient phenotypes, promoting continuity of care, collaboration among healthcare professionals, and integration of technological solutions. The methodology employed involved a multidisciplinary expert group nominated by the EAPC. Through structured literature review, expert consensus, and iterative discussions, the panel defined key components of post-ACS care across different phases of recovery. The final roadmap integrates best available evidence, clinical expertise, and practical considerations to support implementation across diverse healthcare settings.


  • Top Cited Papers

    Patient and public involvement in the management and prevention of cardiovascular disease: a statement of the Association of Cardiovascular Nursing and Allied Professions of the ESC and the ESC Patient Forum

    by Jeroen M Hendriks, Paul McGreavy, Suzanne Fredericks, Ian Jones, James Ainslie, Ana Gomes, Julie Sanders

    Patient and public involvement (PPI) plays a pivotal role in enhancing the management and prevention of cardiovascular disease (CVD), at multiple levels. The partnership with patients and the public, those who are directly affected by CVD, is central to delivering personalized care, and may contribute to decreasing the burden of CVD and reducing health inequalities. This statement describes the concept of PPI and highlights the role of PPI across different settings including: clinical practice, research, regulatory processes, and policy and clinical guideline development. Recognition of the value of PPI and how to create environments and infrastructure to embed PPI into these areas requires further attention, specifically for under-represented communities. Therefore, considerations for good practice as well as future directions for improvement are provided. Whilst the content of this paper focusses on CVD, the insights provided can be applied to other conditions.


  • Open Access

    Risks and benefits of sharing patient information on social media: a digital dilemma

    by Robert M A van der Boon, A John Camm, C Aguiar, E Biasin, G Breithardt, H Bueno, I Drossart, N Hoppe, E Kamenjasevic, R Ladeiras-Lopes, et al.

    Social media (SoMe) has witnessed remarkable growth and emerged as a dominant method of communication worldwide. Platforms such as Facebook, X (formerly Twitter), LinkedIn, Instagram, TikTok, and YouTube have become important tools of the digital native generation. In the field of medicine, particularly, cardiology, attitudes towards SoMe have shifted, and professionals increasingly utilize it to share scientific findings, network with experts, and enhance teaching and learning. Notably, SoMe is being leveraged for teaching purposes, including the sharing of challenging and intriguing cases. However, sharing patient data, including photos or images, online carries significant implications and risks, potentially compromising individual privacy both online and offline. Privacy and data protection are fundamental rights within European Union treaties, and the General Data Protection Regulation (GDPR) serves as the cornerstone of data protection legislation. The GDPR outlines crucial requirements, such as obtaining ‘consent’ and implementing ‘anonymization’, that must be met before sharing sensitive and patient-identifiable information. Additionally, it is vital to consider the patient’s perspective and prioritize ethical and social considerations when addressing challenges associated with sharing patient information on SoMe platforms. Given the absence of a peer-review process and clear guidelines, we present an initial approach, a code of conduct, and recommendations for the ethical use of SoMe. In conclusion, this comprehensive review underscores the importance of a balanced approach that ensures patient privacy and upholds ethical standards while harnessing the immense potential of SoMe to advance cardiology practice and facilitate knowledge dissemination.


  • Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table

    by Francesco Cosentino, Subodh Verma, Philip Ambery, Marianne Bach Treppendahl, Martin van Eickels, Stefan D Anker, Michele Cecchini, Paola Fioretto, Per-Henrik Groop, David Hess, et al.

    Metabolic comorbidities are common in patients with cardiorenal disease; they can cause atherosclerotic cardiovascular disease (ASCVD), speed progression, and adversely affect prognosis. Common comorbidities are Type 2 diabetes mellitus (T2DM), obesity/overweight, chronic kidney disease (CKD), and chronic liver disease. The cardiovascular system, kidneys, and liver are linked to many of the same risk factors (e.g. dyslipidaemia, hypertension, tobacco use, diabetes, and central/truncal obesity), and shared metabolic and functional abnormalities lead to damage throughout these organs via overlapping pathophysiological pathways. The COVID-19 pandemic has further complicated the management of cardiometabolic diseases. Obesity, T2DM, CKD, and liver disease are associated with increased risk of poor outcomes of COVID-19 infection, and conversely, COVID-19 can lead to worsening of pre-existing ASCVD. The high rates of these comorbidities highlight the need to improve recognition and treatment of ASCVD in patients with obesity, insulin resistance or T2DM, chronic liver diseases, and CKD and equally, to improve recognition and treatment of these diseases in patients with ASCVD. Strategies to prevent and manage cardiometabolic diseases include lifestyle modification, pharmacotherapy, and surgery. There is a need for more programmes at the societal level to encourage a healthy diet and physical activity. Many pharmacotherapies offer mechanism-based approaches that can target multiple pathophysiological pathways across diseases. These include sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, selective mineralocorticoid receptor antagonists, and combined glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist. Non-surgical and surgical weight loss strategies can improve cardiometabolic disorders in individuals living with obesity. New biomarkers under investigation may help in the early identification of individuals at risk and reveal new treatment targets.